NO2889310T3 - - Google Patents

Info

Publication number
NO2889310T3
NO2889310T3 NO15155712A NO15155712A NO2889310T3 NO 2889310 T3 NO2889310 T3 NO 2889310T3 NO 15155712 A NO15155712 A NO 15155712A NO 15155712 A NO15155712 A NO 15155712A NO 2889310 T3 NO2889310 T3 NO 2889310T3
Authority
NO
Norway
Application number
NO15155712A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40228991&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2889310(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2889310T3 publication Critical patent/NO2889310T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
NO15155712A 2007-07-06 2008-07-03 NO2889310T3 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94822007P 2007-07-06 2007-07-06
EP08781323.4A EP2170388B1 (en) 2007-07-06 2008-07-03 Anti-cd20 antibody formulations

Publications (1)

Publication Number Publication Date
NO2889310T3 true NO2889310T3 (no) 2018-05-19

Family

ID=40228991

Family Applications (2)

Application Number Title Priority Date Filing Date
NO15155712A NO2889310T3 (no) 2007-07-06 2008-07-03
NO2021036C NO2021036I1 (no) 2007-07-06 2021-09-13 Ofatumumab

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2021036C NO2021036I1 (no) 2007-07-06 2021-09-13 Ofatumumab

Country Status (38)

Country Link
US (2) US20110020328A1 (no)
EP (2) EP2889310B1 (no)
JP (1) JP5529017B2 (no)
KR (2) KR20100038092A (no)
CN (1) CN101820912B (no)
AR (2) AR067455A1 (no)
AU (1) AU2008275278B2 (no)
BR (2) BRPI0814003B1 (no)
CA (1) CA2692681C (no)
CL (1) CL2008001984A1 (no)
CO (1) CO6270340A2 (no)
CR (1) CR11249A (no)
CY (2) CY1118419T1 (no)
DK (2) DK2889310T3 (no)
DO (1) DOP2010000001A (no)
EA (1) EA017994B1 (no)
ES (2) ES2610821T3 (no)
FR (1) FR21C1040I1 (no)
HK (2) HK1207652A1 (no)
HR (2) HRP20170033T1 (no)
HU (3) HUE031288T2 (no)
IL (1) IL202950A (no)
JO (1) JO3219B1 (no)
LT (3) LT2170388T (no)
MA (1) MA31471B1 (no)
MX (1) MX2010000017A (no)
NO (2) NO2889310T3 (no)
NZ (1) NZ582250A (no)
PE (1) PE20090738A1 (no)
PL (2) PL2170388T3 (no)
PT (2) PT2889310T (no)
SI (2) SI2170388T1 (no)
TR (1) TR201802928T4 (no)
TW (2) TWI612060B (no)
UA (1) UA107557C2 (no)
UY (1) UY31210A1 (no)
WO (1) WO2009009407A1 (no)
ZA (1) ZA200909107B (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
UA107557C2 (xx) * 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
EP2173163A4 (en) * 2007-07-06 2010-12-08 Glaxosmithkline Llc ANTIBODY FORMULATIONS
SI3409289T1 (sl) 2010-02-26 2020-12-31 Novo Nordisk A/S Stabilni sestavki, ki vsebujejo protitelo
LT2542257T (lt) 2010-03-01 2017-11-27 Bayer Healthcare Llc Optimizuoti monokloniniai antikūnai prieš audinių faktoriaus kelio slopiklį (tfpi)
CN102905692B (zh) 2010-05-28 2015-09-16 诺沃—诺迪斯克有限公司 包含抗体和防腐剂的稳定的多剂量组合物
JP2014510152A (ja) * 2011-04-07 2014-04-24 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 粘度が低減された処方物
MX367097B (es) * 2011-05-02 2019-08-05 Millennium Pharm Inc FORMULACION PARA ANTICUERPO ANTI-A4ß7.
WO2012151199A1 (en) 2011-05-02 2012-11-08 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
UY34105A (es) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
CA3162739A1 (en) * 2013-03-12 2014-10-02 Primal Therapies, Inc. Dental composition comprising chelator and base
EP2805730A1 (en) * 2013-05-21 2014-11-26 Bergen Teknologioverforing AS Nitric oxide donor for the treatment of chronic fatigue syndrome
WO2015162504A1 (en) 2014-04-23 2015-10-29 Novartis Ag Novel dosing and uses of ofatumumab
WO2016189491A1 (en) * 2015-05-28 2016-12-01 Glaxosmithkline Intellectual Property Development Limited Novel formulation
CN109563161A (zh) * 2016-02-03 2019-04-02 安口生物公司 用于提高抗体稳定性的缓冲制剂
JP6851391B2 (ja) 2016-08-15 2021-03-31 ノバルティス アーゲー オファツムマブを用いた多発性硬化症の治療レジメンおよび治療方法
WO2018179138A1 (ja) * 2017-03-29 2018-10-04 持田製薬株式会社 抗体含有液体製剤
US10799597B2 (en) 2017-04-03 2020-10-13 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
RU2019138507A (ru) 2017-05-02 2021-06-02 Мерк Шарп И Доум Корп. Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1
CA3033195A1 (en) * 2018-02-09 2019-08-09 Ecolab Usa Inc. Flowability testing systems and methods
ES2957112T3 (es) 2019-09-11 2024-01-11 Novartis Ag Tratamiento del RMS mediante cambio de terapia
CA3152192A1 (en) 2019-09-11 2021-03-18 Novartis Ag Management of conditions other than multiple sclerosis in ofatumumab-treated patients
CN112675126A (zh) * 2019-10-18 2021-04-20 百奥泰生物制药股份有限公司 抗cd20抗体制剂及其应用
AU2021253674A1 (en) 2020-04-09 2022-11-03 Novartis Ag Ofatumumab for treating MS while maintaining serum IgG
JP7057954B2 (ja) * 2020-09-03 2022-04-21 国立大学法人大阪大学 改善された保存安定性を有するタンパク質含有液体製剤
KR20230170923A (ko) 2021-04-14 2023-12-19 노파르티스 아게 아시아인 환자들에서 ms 치료용 오파투무맙
KR20240046200A (ko) 2021-08-16 2024-04-08 노파르티스 아게 소아 ms 치료를 위한 오파투무맙
KR20230150203A (ko) * 2022-04-20 2023-10-30 주식회사 알토스바이오로직스 오크렐리주맙(Ocrelizumab)을 포함하는 약학적 조성물과 그의 용도

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4816401A (en) * 1985-09-09 1989-03-28 University Of Rochester Serum free cell culture medium
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2241710T3 (es) 1991-11-25 2005-11-01 Enzon, Inc. Procedimiento para producir proteinas multivalentes de union a antigeno.
ES2190087T3 (es) * 1997-06-13 2003-07-16 Genentech Inc Formulacion estabilizada de un anticuerpo.
PL211886B1 (pl) * 1999-10-04 2012-07-31 Novartis Vaccines & Diagnostic Stabilizowana ciekła kompozycja farmaceutyczna, sposób zwiększania trwałości polipeptydu, sposób zwiększania trwałości podczas przechowywania kompozycji, sucha postać kompozycji oraz preparat zawierający kompozycję
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
CA2476166C (en) 2002-02-14 2011-11-15 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
PL215168B1 (pl) * 2002-02-27 2013-10-31 Immunex Corp Formulacja polipeptydowa
CA2490423A1 (en) * 2002-06-21 2003-12-31 Biogen Idec Inc. Buffered formulations for concentrating antibodies and methods of use thereof
ES2744275T3 (es) * 2002-10-17 2020-02-24 Genmab As Anticuerpos monoclonales humanos contra CD20 para su uso en el tratamiento de esclerosis múltiple
NZ541050A (en) * 2002-12-16 2010-06-25 Genmab As Human monoclonal antibodies against interleukin 8 (IL-8)
US8084582B2 (en) * 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
AR044388A1 (es) 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
US20090110681A1 (en) * 2005-03-08 2009-04-30 Pfizer, Inc. Anti-M-CSF Antibody Compositions
PL1942939T5 (pl) * 2005-09-30 2021-10-11 Medimmune Limited Kompozycja przeciwciała interleukiny-13
UA107557C2 (xx) * 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
EP2173163A4 (en) * 2007-07-06 2010-12-08 Glaxosmithkline Llc ANTIBODY FORMULATIONS

Also Published As

Publication number Publication date
DK2170388T3 (en) 2017-01-16
CO6270340A2 (es) 2011-04-20
HRP20180440T1 (hr) 2018-04-20
TWI612060B (zh) 2018-01-21
HK1207652A1 (en) 2016-02-19
JO3219B1 (ar) 2018-03-08
BRPI0814003A2 (pt) 2015-02-03
CY1120047T1 (el) 2018-12-12
UY31210A1 (es) 2009-01-30
JP5529017B2 (ja) 2014-06-25
ES2663504T3 (es) 2018-04-13
US20110020328A1 (en) 2011-01-27
PT2889310T (pt) 2018-03-26
TW201623334A (zh) 2016-07-01
MX2010000017A (es) 2010-04-07
US20150158951A1 (en) 2015-06-11
PL2889310T3 (pl) 2018-06-29
AR067455A1 (es) 2009-10-14
HRP20170033T1 (hr) 2017-03-24
NO2021036I1 (no) 2021-09-13
LTPA2021520I1 (no) 2021-10-11
CA2692681A1 (en) 2009-01-15
IL202950A0 (en) 2011-08-01
IL202950A (en) 2014-05-28
EP2889310A1 (en) 2015-07-01
AU2008275278B2 (en) 2011-04-14
ZA200909107B (en) 2012-12-27
PL2170388T3 (pl) 2017-06-30
TWI515204B (zh) 2016-01-01
CY1118419T1 (el) 2017-06-28
NZ582250A (en) 2012-04-27
UA107557C2 (xx) 2015-01-26
SI2170388T1 (sl) 2017-01-31
PE20090738A1 (es) 2009-07-18
CL2008001984A1 (es) 2009-01-09
CA2692681C (en) 2018-12-04
EP2170388B1 (en) 2016-10-12
KR101670454B1 (ko) 2016-10-31
BRPI0814003B1 (pt) 2021-06-15
CR11249A (es) 2010-03-08
AR109461A2 (es) 2018-12-12
WO2009009407A1 (en) 2009-01-15
HUE031288T2 (hu) 2017-06-28
HUE038501T2 (hu) 2018-10-29
MA31471B1 (fr) 2010-06-01
CN101820912A (zh) 2010-09-01
BR122020026978B1 (pt) 2021-09-28
DK2889310T3 (en) 2018-03-26
SI2889310T1 (en) 2018-04-30
FR21C1040I1 (fr) 2021-11-19
EP2170388A1 (en) 2010-04-07
HUS2100038I1 (hu) 2021-10-28
CN101820912B (zh) 2014-03-12
ES2610821T3 (es) 2017-05-03
HK1141979A1 (zh) 2010-11-26
PT2170388T (pt) 2017-01-04
LT2170388T (lt) 2017-01-10
JP2011526880A (ja) 2011-10-20
EP2170388A4 (en) 2011-07-06
KR20100038092A (ko) 2010-04-12
EA201070105A1 (ru) 2010-08-30
AU2008275278A1 (en) 2009-01-15
KR20150088335A (ko) 2015-07-31
DOP2010000001A (es) 2010-01-31
TR201802928T4 (tr) 2018-03-21
EP2889310B1 (en) 2017-12-20
LT2889310T (lt) 2018-03-26
TW200914466A (en) 2009-04-01
EA017994B1 (ru) 2013-04-30

Similar Documents

Publication Publication Date Title
LTPA2021520I1 (no)
CN300840222S (zh) 布(46)
CN300732052S (zh) 包装盒(增氧活水器)
CN300726124S (zh) 牙刷(钻石镶嵌)
CN300731680S (zh) 纯银保健杯(花开富贵)
CN300726281S (zh) 墙纸(23)
CN300726330S (zh) 沙发(711a)
CN300726512S (zh) 侧装西裤架(f23)
CN300726674S (zh) 电热水壶(mk-15s03a)
CN300726918S (zh) 包装盒
CN300726936S (zh) 包装盒(不裂神乳霜)
CN300727148S (zh) 包装袋(安力嘉·学生配方奶粉400克)
CN300727174S (zh) 包装袋(卫生巾)
CN300728453S (zh) 拖车尾灯架(pvc组套)
CN300728485S (zh) 汽车芳香剂盒
CN300731585S (zh) 组合柜(c306a)
CN300728800S (zh) 玻璃(富贵纹)
CN300728863S (zh) 沙发(nb628一位)
CN300728881S (zh) 椅(ct-285)
CN300728896S (zh) 床(vm010)
CN300728926S (zh) 桌子(6)
CN300729127S (zh) 电热炉(hp2001-3)
CN300870579S (zh) 装饰板(fs068)
CN300728502S (zh) 冰淇淋机
CN300729504S (zh) 包装盒(维生素c咀嚼片竖画)